Companies · GDRX
GoodRx
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 6, 2026
GoodRx Q2 2026: Pharma Direct surges 76% YoY, raising full-year guidance as subscription pivot accelerates ahead of plan
GoodRx delivered Q2 2026 revenue of $200.4 million with adjusted EBITDA of $63.7 million (31.8% margin), driven by Pharma Direct growing 76% year-over-year to $61.6 million — now 31% of total revenue — as manufacturer adoption of consumer direct pricing programs, particularly in GLP-1s, accelerates faster than management anticipated. The company raised full-year revenue guidance to $790-$805 million and adjusted EBITDA guidance to $240-$250 million, with Pharma Direct now expected to grow more than 70% for the full year versus a prior 50% expectation. Subscription revenue grew 39% YoY to $28.5 million, supported by the May launch of GoodRx Companion, while prescription transactions revenue of $106.4 million declined as the company deliberately redirects marketing and product investment toward higher-lifetime-value subscription offerings.
Tone: bullishRevenue
$796.9M
GDRX 10-K · FY 2025
Employees
697
Revenue growth YoY
+1%
Founded
2011
Profile
GDRX 10-K Item 1 · Feb 26, 2026GoodRx is a consumer-focused digital healthcare platform that provides price transparency and affordability solutions for prescription medications across the United States. The company operates a prescription marketplace, subscription savings programs, telehealth services, and a pharma direct offering for brand medications. GoodRx earns revenue by connecting consumers with PBMs, pharmacies, and pharma manufacturers through its proprietary pricing engine.
Read filing description ↓ Collapse description ↑
GoodRx was founded to solve the challenges that consumers face in understanding, accessing, and affording healthcare by removing the friction and inefficiencies in the system. We started with a price comparison tool for prescriptions, offering consumers free access to lower prices on their medication. This price comparison platform processes over 420 billion pricing data points every day and integrates that data into a user-friendly interface which provides consumers with dynamic, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States. Today, we believe our expanded platform improves the health and financial well-being of American families by providing easy access to price transparency and affordability solutions for generic and brand medications both for consumers and healthcare providers, other healthcare product and services, including certain condition-specific end-to-end solutions, telehealth services, and wellness related content. We believe that our offerings provide significant savings to consumers, and can help drive greater medication awareness, access and adherence, faster treatment and better patient outcomes that also benefit the broader healthcare ecosystem and its stakeholders. We see exciting growth potential as we continue to expand our role as an essential access and affordability layer across the healthcare ecosystem serving consumers, healthcare providers, pharmacies, and pharma manufacturers across the United States.
Primary products
- Prescription Transactions Offering
- Gold
- RxSmartSaver+
- Condition-Specific Subscriptions
- Pharma Direct Offering
- GoodRx Care (telehealth)
Business segments
End markets
Geographies
Named customers
A limited number of PBMs generate a significant percentage of the discounted prices that we present through our platform and, as a result, we generate a significant portion of our revenue from contracts with a limited number of PBMs.
“We believe that we are able to compete effectively against these organizations based on our brand, scale, pricing, and consumer experience.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue increased 1% to $796.9 million in 2025 from $792.3 million in 2024, reflecting modest growth despite headwinds from Rite Aid store closures and a material volume reduction in an integrated savings program.
The rest of GDRX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.